The Pharmaceutical Market: Spain

SUMMARY

The Spanish pharmaceutical market is the fifth largest in the EU-15 and the seventh in the world. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

In June 2006, Spain approved a new pharmaceutical law, Ley de Garantias y Uso Racional de los Medicamentos y Productos Sanitarios (Ley 29/2006). The new law has been effective since July 2006 and replaces the previous pharmaceutical law, Ley de Medicamentos (Ley 25/1990), issued in 1990. The new law incorporates Directive 2004/27/EC for human pharmaceuticals and Directive 2004/28/EC for veterinary pharmaceuticals. Also, it harmonises the national regulation with Europe, under Regulation 2004/726/EC.

Under the new pharmaceutical law, the government has started to work on the regulatory framework for the new Reference Price System (RPS), to be operational on 1st March 2007. The new RPS aims to be more transparent and will promote generics. The previous RPS, introduced by the conservative party in January 2004, was suspended in 2005. As an alternative, the government introduced drug price cuts and reduced wholesalers' margins in March 2005 and 2006, in an effort to sustain the SNS system.

The Spanish pharmaceutical market is the fifth largest in the EU-25, valued at US$21.0 billion in 2006. The pharmacy sector represented 76.9% of the market at manufacturers' prices in 2005. Almirall Prodesfarma and Esteve are the leading domestic producers, with sales valued at US$1.2 billion and US$1.0 billion, respectively, in 2005. Their annual R&D investment has risen sharply in recent years. In fact, Almirall opened a new state-of-the-art R&D centre in Barcelona in May 2006, with investments valued at US$151 million. Esteve continues to enhance its market presence in China, with a second joint-venture established with Huadong's Yiwu Huayi in January 2006.

The generics sector continues to grow, and currently represents 11.6% of the pharmacy sector by volume. One of the latest companies to invest in the sector is the Indian Wanbury Ltd, which announced the acquisition of Cantabria Farmaceutica's branded generic medicines in October 2006. The trade association AESEG represents 24 generic producers which account for 80.0% of the sector. As 15 leading new active ingredients will lose their patents in the next years, further opportunities will arise for the sector.

TABLE OF CONTENTS

SPAIN: BACKGROUND DATA

• GEOGRAPHY
• POLITICAL OVERVIEW
• ECONOMIC OVERVIEW
• GDP Projections, 2005-2011
• POPULATION
• Projected Population, 2005-2011
• Census Population, 2001
• Population by Region & Province, 1991 Census, 2001 Census & 2005
• DEMOGRAPHIC INDICATORS
• Demographic Indicators, 1999-2005
• MORTALITY
• Selected Mortality Trends, 1999-2004
• Selected Mortality Trends, 1999-2004 (%)
• Change in Selected Mortality Trends, 1999-2004 (%)
• Deaths by Cause, 1999-2004
• MORBIDITY
• Selected Reportable Infectious Diseases, 1999-2004
• AIDS
• AIDS Cases by Cause of Infection, 2005
• AIDS Cases by Region/Area, 2005
• HIV

CHARTS

• Map of Spain
• Leading Causes of Death, 2004 (%)
• AIDS Cases, 1992-2003 (Rate per Million Population)

SPAIN: HEALTHCARE SYSTEM

• ORGANISATION & ADMINISTRATION
• Health Cohesion & Quality Law
• Health Insurance
• HEALTH EXPENDITURE
• Projected Health Expenditure, 2006-2011
• Health Expenditure, 1990-2003 (Million Euros)
• Change in Health Expenditure, 1990-2003 (%)
• Public Health Expenditure
• Public Health Expenditure by Type, 2004-2005 (Million Euros)
• Public Health Expenditure by Sector, 2003
• HOSPITAL SERVICES
• Hospitals by Ownership & Region, 2005
• Public Hospitals by Ownership & Region, 2005
• Private Hospitals by Ownership & Region, 2005
• Hospitals by Provision & Region, 2005
• Public Hospitals by Provision & Region, 2005
• Private Hospitals by Provision & Region, 2005
• Hospitals by Provision & Specialty, 2005
• Public Hospitals by Provision & Specialty, 2005
• Private Hospitals by Provision & Specialty, 2005
• Hospitals, 1985-2005
• Hospital Beds by Ownership & Region, 2005
• Public Hospital Beds by Ownership & Region, 2005
• Private Hospital Beds by Ownership & Region, 2005
• Hospital Beds by Provision & Region, 2005
• Public Hospital Beds by Provision & Region, 2005
• Private Hospital Beds by Provision & Region, 2005
• Hospital Beds by Provision & Specialty, 2005
• Public Hospital Beds by Provision & Specialty, 2005
• Private Hospital Beds by Provision & Specialty, 2005
• Hospital Beds, 1985-2005
• High Technical Hospital Equipment by Region, 2005
• High Technical Hospital Equipment, 1995-2005
• Hospital Resources
• Hospitals by Specialty, 2003
• Hospital Resources by Specialty, 2003
• Hospital Resources by Provision, 2003
• Hospital Resources in Use by Specialty, 2003
• Hospital Resources in Use by Provision, 2003
• Hospital Activity
• Hospital Activity by Specialty, 2003
• Hospital Activity by Provision, 2003
• Hospital Discharges by Hospital Type & Specialty, 2003
• Hospital Discharges by Provision & Specialty, 2003
• Hospital Discharges, 1993-2003
• Summary of Consultations, 2003
• Consultations in Hospitals by Specialty, 2003
• Consultations in Specialised Centres by Specialty, 2003
• First Consultations in Hospitals & Centres by Specialty, 2003
• Total Consultations in Hospitals & Centres by Specialty, 2003
• Consultations, 1993-2003
• Diagnostic Procedures by Provision, 2003
• Diagnostic Procedures, 1992-2003 (000)
• Surgical Procedures by Type & Specialty, 2003
• Surgical Procedures by Provision & Specialty, 2003
• Surgical Procedures, 1995-2003
• Obstetric Hospital Activity by Provision, 2003
• Births, 1995-2003
• AMBULATORY CARE
• Primary Care Consultations, 1994 & 2003
• MEDICAL PERSONNEL
• Registered Medical Personnel, 1995-2005
• Practising Medical Personnel, 2005
• Registered Doctors, Pharmacists & Nurses by Region, 2005
• Public Medical Personnel
• Personnel in Health Centres & Public Hospitals by Specialty, 2003
• Doctors in Health Centres & Public Hospitals by Specialty, 2003

CHARTS

• Ministry of Health & Consumer Affairs' Organisation, 2003/2004
• Projected Health Expenditure, 2006-2011
• Health Expenditure as Percentage of GDP, 1990-2003
• Public Health Expenditure as Percentage of Total, 1990-2003
• Public Health Expenditure, 1990-2005
• Public Health Expenditure by Type, 2005 (%)
• Hospitals by Type, 2005
• Hospitals, 1985-2005
• Beds by Hospital Type, 2005
• Hospital Beds, 1985-2005
• Hospital Resources, 2003
• Hospital Activity by Selected Hospital Type & Provider, 2003 (%)
• Hospital Discharges by Selected Hospital Type & Provider, 2003
• First Consultations by Specialty as Percentage of Total Consultations, 2003
• Diagnostic Procedures by Provision, 2003 (%)
• Surgical Procedures by Provision & Specialty, 2003 (%)
• Births by Provision, 2003
• Registered Doctors, 1999-2005
• Doctors in Health Centres & Public Hospitals by Specialty, 2003

SPAIN: ACCESSING THE PHARMACEUTICAL MARKET

• INTRODUCTION
• REGULATORY ENVIRONMENT
• European Pharmaceutical Regulation
• European Pharmaceutical Legislation, 2004
• Implications for Generics Derived from the Compromise Package, December 2003
• National Pharmaceutical Regulation
• Generics Regulatory Environment, 1996-2004
• Patent Protection & Intellectual Property Rights
• Drug Registrations
• Drug Registrations, 2003-2004
• New Drug Approvals
• Drug New Approvals, 1992-2005
• Notifications of Adverse Reactions
• Notifications of Adverse Reactions, 1984-2004
• Pricing & Reimbursement
• Reference Price System, 2000-2004
• Promotion
• DISTRIBUTION CHANNELS
• Distributors
• Federacio Farmaceutica
• Grupo Cofares
• Grupo SAFA
• Hefame
• Pharmacies
• Pharmacies, 1990-2005
• Pharmacies by Region, 2005
• TRADE FAIRS
• Farmamaq
• Farma Meeting
• Infarma
• Medical Expo Forum
• DOMESTIC PRODUCTION
• Pharmaceutical Production, 1995-2002
• Trade Associations
• AESEG
• Members of EASEG, 2006
• ANEFP
• Members of ANEFP, 2006
• FARMAINDUSTRIA
• Members of FARMAINDUSTRIA, 2006
• Members of FARMAINDUSTRIA by Size, 2005
• Domestic Producers
• Almirall
• Cantabria Farmaceutica
• Esteve
• FAES
• Farmasierra
• Ferrer Internacional
• Grifols
• Lacer
• Salvat
• Uriach
• Zeltia / PharmaMar
• Multinational Producers
• AstraZeneca
• Bayer
• Berna Biotech
• Boehringer Ingelheim
• Gideon Pharma
• GlaxoSmithKline
• Elli Lilly
• Menarini
• Merck KGaA
• Merck Sharp & Dohme
• Novartis
• Novartis Espana's Sales by Division, 2000-2004 (Million Euro)
• Ranbaxy
• Roche
• Sanofi-Aventis
• Research & Development
• DIRECTORY
• Government Organisations
• Trade Associations

CHARTS

• Notifications of Adverse Reactions, 1984-2004
• Pharmacies, 1990-2005
• Pharmacies by Region, 2005
• Almirall's Total Sales, 2002-2006
• Almirall's Total Revenues, 2002-2006
• Almirall's R&D Expenditure, 2002-2006
• Esteve's Figures, 2004-2005 (Million Euro)
• Esteve's Sales, 1995-2005 (Million Euro)
• FAES' Consolidated Sales, 2002-2006
• Ferrer's Sales by Therapeutic Area, (%)
• Lacer's Turnover, 1998-2005
• Salvat's Sales by Division, (%)
• Salvat's Sales by Therapeutic Area, (%)
• AstraZeneca's Sales by Therapeutic Area, 2005 (%)
• Quimica Farmaceutica Bayer, 2004-2005 (Million Euro)
• Eli Lilly's Personnel, 1995-2005
• Eli Lilly's R&D Expenditure, 1993-2005
• Novartis Espana's Sales, Exports, Investments & R&D Expenditure, 2002-2004 (Million Euro)
• Roches's Sales & Personnel, 2005
• Pharmaceutical R&D Expenditure, 2000-2005